Full Press Release Details
InMed Expands Patent Portfolio with Novel Cannabinoid
Advances Collaboration Agreement with Leading Cannabinoid Research Expert
Vancouver, BC and South San Francisco, CA -
April 28, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in
the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the publication of a patent
application in North America for several cannabinoid analogs. This patent application has broad claims directed to their molecular structure,
uses and methods of manufacturing.
Entitled "Cannabinoid Analogs and Methods
for their Preparation", the patent application describes several new cannabinoid-related chemical compounds that have not been previously
described. If granted, the broad patent application allows for the creation of several variations of novel cannabinoid compounds, producing
a robust library of proprietary new chemical entities ( NCEs').
Scientists at BayMedica, LLC, InMed's subsidiary
in the US, designed and produced these cannabinoid analogs. These NCEs are expected to offer similar or improved therapeutic effects compared
to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases.
Eric Hsu, SVP, Pre-Clinical Research and Development
for InMed commented; "We believe rare cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical
needs. This patent covers the selective modification of naturally occurring cannabinoids to target specific properties for pharmaceutical
development. Such patent protection is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D."
InMed has initiated a research collaboration with
the Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila (Italy) in the laboratory of Dr. Mauro
Maccarrone, an international expert in cannabinoid research and founding member of the European Cannabinoid Research Alliance. He is also
the 2007 recipient of the International Association for Cannabinoid Medicines's prestigious Ester Fride Award for Basic Research,
and the 2016 recipient of the International Cannabinoid Research Society's prestigious Mechoulam Award. Dr. Maccarrone's lab
will be screening the Company's novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses.
Creating a robust patent library of NCEs
The patent application covers technology that
allows for the creation of libraries of NCEs that can be compared to other drugs in order to select candidates for advancement. The cannabinoid
analogs were manufactured in a biosynthetic process using the yeast S. cerevisiae, which is commonly used to produce therapeutic
biologicals and vaccines.
Filing this patent application in a number of
global jurisdicitions further emphasizes the Company's commitment towards developing NCEs and enhancing rare cannabinoids R&D
Why pursue cannabinoid analogs?
Unlike natural cannabinoids isolated from the
plant which are not patentable, these cannabinoid analogs are patentable. Benefits may include:
Learn more about InMed's Cannabinoid Analogs:
Novel Patentable Cannabinoid Analogs | InMed Pharmaceuticals
Learn more about InMed's Cannabinoids in Development: https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/
About InMed: InMed Pharmaceuticals
is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary
BayMedica, LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including
pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics
and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more
information, visit www.inmedpharma.com and www.baymedica.com.
Senior Director, Investor Relations
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to
a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Forward-looking information in this news release includes statements about: expanding patent portfolio with novel cannabinoid analogs;
advancing collaboration agreement with leading cannabinoid research expert; screening analogs for therapeutic uses;publication of patent
application in North America for several cannabinoids analogs; the patent has broad claims directed to molecular structure, uses and methods
of manufacturing; NCEs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid
with modifications that may make them preferred candidates to treat specific diseases; cannabinoids hold tremendous therapeutic potential
that may address a number of unmet medical needs; patent application covering technology that allows for the creation of libraries of
NCEs that can be compared to other drugs in order to select candidates for advancement; screening the Company's novel cannabinoid
analogs to investigate pharmacological properties and potential therapeutic uses; benefits of analogs that may include targeting certain
physiological outcomes in specific diseases, improving upon the safety profile of the natural cannabinoids; enhancing the ability to integrate
with specific delivery technologies; protecting the long-term research investment and commercial opportunities; being a global leader
in the research, development, manufacturing and development of rare cannabinoids; and delivering new treatment alternatives to patients
that may benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking
information contained in this news release, InMed has made numerous assumptions. While InMed considers these assumptions to be reasonable,
these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are
known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and
other filings with the Security and Exchange Commission on www.sec.gov.
All forward-looking information
herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking
information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect
future results, events or developments, except as required by law.